Table 1.
Patients and lesions characteristics
| Characteristic | Number (%) |
|---|---|
| Patient number | 40 (100%) |
| Age (median, range) | 55 years (38–79 years) |
|
Sex Male Female |
24 (60%) 16 (40%) |
|
Comorbidity Diabetes *CVD |
5 (12.5%) 8 (20%) |
|
Primary diagnosis Lung Breast Renal cell carcinoma Other |
24 (60%) 10 (25%) 2 (5%) 4 (10%) |
| Metastasis diameter (mm, median, range) | 19.5 mm (2–45 mm) |
| Metastasis volume (cc, median, range) | 2.3 cc (0.01–32.1 cc) |
|
Lesion location Frontal Parietal Temporal Occipital Brain stem Basal ganglia Other |
12 (30%) 14 (35%) 6 (15%) 1 (2.5%) 2 (5%) 2 (5%) 3 (7.5%) |
|
RT treatments on RN lesion before SRS **WBRT Previous SRS WBRT + previous SRS None |
13 (32.5%) 6 (15%) 4 (10%) 17 (42.5%) |
| Other brain lesion SRT | 28 (70%) |
| SRS/SRT total dose (median, range) | 20 Gy (11–24 Gy) / 27 Gy (21–30 Gy) |
| SRT fraction number (median, range) | 3 (3-5) |
| †BED3 of SRS/SRT (median, range) | 153 Gy (51.3–216 Gy) / 99 Gy (67–108) |
| ‡BED10 of SRS/SRT (median, range) | 60 Gy (23.1–82 Gy) / 49.6 Gy (35.7–51.3) |
| Total BED3 (median, range) | 148 Gy (51.3–346 Gy) |
*CVD-cardiovascular disease.
**WBRT-Whole Brain Radiation Therapy.
†BED3-Biologically Effective Dose for late responding tissue, alpha/beta equals 3.
‡ BED3-Biologically Effective Dose for early responding tissue, alpha/beta equals 10 BED = nd[1 + d/(α/β)] where n = number of fractions, d = fraction dose.